Endogenex
Endogenex is a clinical-stage medical technology company developing the pulsENDO system, an endoscopic procedure that uses non-thermal pulsed electric fields to regenerate duodenal signaling cells and treat type 2 diabetes in adults with inadequately controlled blood glucose.
- Company typePrivate
- Founded2002
- HeadquartersPlymouth, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Endogenex does
Endogenex is a clinical-stage medical technology company developing the pulsENDO system, an endoscopic procedure that delivers non-thermal pulsed electric fields (PEF) to the mucosa and submucosa of the duodenum to regenerate healthy metabolic signaling cells for the treatment of type 2 diabetes. The company targets adults with type 2 diabetes whose blood glucose is inadequately controlled by existing glucose-lowering medications, an addressable population of more than 400 million people globally. Its core technology consists of a specialized catheter-based endoscopic delivery system that applies controlled electrical pulses to disrupt poorly functioning cells and induce regeneration, with a second-generation dose-response catheter design demonstrating a clear dose-metabolic response relationship in the 48-week REGENT-1 study (mean HbA1c reduction of 1.5%, fasting plasma glucose reduction of 2.3 mmol/L, body weight loss of 5.4 kg at the highest treatment intensity, with 100% procedural technical success and no device-related serious adverse events).
The company was founded in 2002 in partnership with Mayo Clinic and is headquartered in Plymouth, Minnesota. Endogenex has received FDA Breakthrough Device Designation and FDA Investigational Device Exemption approval for the ReCET pivotal study, a multicenter, prospective, randomized, double-blinded, sham-controlled trial enrolling up to 350 patients at approximately 40 sites in the United States and Australia, with first patient enrolled in October 2024. The company's expected business model is medical device hardware sales targeting gastroenterologists, endocrinologists, and diabetes specialists at hospitals and ambulatory surgery centers, although the product is currently investigational and not for sale in any geography. The company is privately held and has raised approximately $162.9 million in total documented funding, including a $138 million Series C financing completed across two rounds ($88M in June 2024 and a $50M extension in March 2026 led by Arboretum Ventures).
Endogenex firmographics
Firmographics- Name
- Endogenex
- Legal name
- Endogenex, Inc.
- Website
- https://endogenex.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Endogenex is a clinical-stage medical technology company developing the pulsENDO system, an endoscopic procedure that uses non-thermal pulsed electric fields to regenerate duodenal signaling cells and treat type 2 diabetes in adults with inadequately controlled blood glucose.
- Ownership category
- akta.pro rank
Endogenex industry classification
Industry- Product category
- Endoscopic Medical Devices for Metabolic Disease
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro industry
- Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR EquipmentDiabetes (General)
Keywords
Where Endogenex is headquartered
LocationHeadquarters
- HQ city
- Plymouth
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Endogenex business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales (Future): Endogenex is a clinical-stage medical technology company developing the pulsENDO system for type 2 diabetes treatment. Once FDA approved, the company intends to commercialize its endoscopic procedure as a treatment option for patients with inadequately controlled type 2 diabetes. The product is described as investigational and not for sale in any geography as of the current date.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Endogenex product offering
Product offeringCore offering
Endogenex is developing the pulsENDO System, a catheter-based endoscopic medical device that delivers non-thermal pulsed electric fields to the mucosa and submucosa of the duodenum. The procedure targets poorly functioning signaling cells to induce regeneration of healthy cells, with the goal of restoring metabolic function and helping patients with type 2 diabetes regain control of their blood glucose levels. The system is investigational, not yet approved for commercial sale, and is being evaluated in the pivotal ReCET Clinical Study for FDA approval.
Product overview
Endogenex offers the pulsENDO System as its core product technology, which uses non-thermal pulsed electric fields delivered via a specialized catheter through an endoscopic procedure to treat inflamed duodenal tissue. The ReCET System represents the clinical study application of this technology. The pulsENDO catheter is inserted through the mouth into the duodenum where it delivers controlled electrical pulses to regenerate healthy cells. Both products work as a unified system—the pulsENDO is the technology platform while ReCET is the branded clinical application being evaluated in pivotal trials. The system is investigational and not yet approved for commercial sale.
Differentiator
Problem solved
Functional benefit
Products and services
- pulsENDO System An endoscopic system that delivers non-thermal pulsed electric fields to the mucosa and submucosa of the duodenum to regenerate healthy metabolic signaling cells and restore metabolic function. It is intended as a single outpatient procedure for adults with type 2 diabetes inadequately controlled by glucose-lowering medications. The system is investigational, limited by federal law to investigational use, and not for sale in any geography.
- ReCET System (Recellularization of Enterocrine Tissues) The clinical branded application of the pulsENDO technology, evaluated in the pivotal ReCET Clinical Study. The ReCET System is being assessed for safety and effectiveness in adult patients with type 2 diabetes inadequately controlled by non-insulin, glucose-lowering medications at up to 40 sites in the United States and Australia, enrolling approximately 350 patients.
Quantifiable outcome
- Mean HbA1c reduction of 1.5% at 48 weeks with highest treatment intensity
- +6 more outcomes
Companies that use Endogenex
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles2 records
Endogenex technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Endogenex partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Mayo CliniccoreEndogenex was founded in partnership with Mayo Clinic. Mayo Clinic provides clinical expertise, research collaboration, and co-development of the technology. Dr. Barham Abu Dayyeh from Mayo Clinic serves as Co-inventor and Co-Principal Investigator for the ReCET Study. Mayo Clinic is also an investor in the company.
- Cuyuna Regional Medical CenterminorClinical trial site where Dr. Paul Severson serves as clinical investigator and has provided endorsement of the pulsENDO procedure as a treatment opportunity for type 2 diabetes patients.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Endogenex competitors and assessment
Company assessmentDirect peers
- Fractyl Health: Fractyl Health is the most direct competitor to Endogenex, developing Revita (Duodenal Mucosal Resurfacing), a catheter-based endoscopic procedure that ablates the duodenal mucosa to treat T2D. Both companies target duodenal tissue regeneration as a root-cause T2D therapy using endoscopic catheter delivery systems.
Emerging players
- Allurion Technologies: Allurion develops the Allurion Balloon, a swallowable, endoscopy-free gastric balloon for weight loss. It is comparable to Endogenex as a procedural, non-pharmacologic metabolic intervention targeting obesity-related metabolic disease with a similar outpatient, single-procedure commercial model.
- Spatz Medical: Spatz Medical develops the Spatz3 Adjustable Gastric Balloon, an endoscopic weight loss balloon. Comparable to Endogenex as a procedural endoscopic metabolic intervention with a similar single-procedure commercial model, though targeting obesity rather than T2D directly.
- ReShape Lifesciences: ReShape Lifesciences develops the Lap-Band adjustable gastric banding system and other metabolic intervention products. Comparable to Endogenex as a procedural metabolic intervention company targeting obesity-related metabolic disease with similar outpatient procedural commercial models.
Broad incumbents
- Medtronic: Medtronic is a major diabetes device incumbent with insulin pumps, CGM-adjacent products, and a large diabetes sales force. While Endogenex targets a different mechanism (procedural duodenal intervention vs. insulin delivery), Medtronic represents a potential strategic acquirer and the dominant player in the diabetes device market Endogenex would enter.
- Dexcom: Dexcom is the market leader in continuous glucose monitoring (CGM) for T2D and T1D management. While not a direct competitor in mechanism, Dexcom represents the dominant non-pharmacologic monitoring technology used by T2D patients, and could be a complementary or competitive technology to Endogenex's procedural therapy.
- Insulet: Insulet manufactures the Omnipod tubeless insulin pump, a major T2D and T1D management device. Like Medtronic, Insulet is an established diabetes device incumbent with deep payer coverage and prescriber relationships, representing both a strategic acquirer and a competitor for physician mindshare in T2D treatment.
- Boston Scientific: Boston Scientific is a major endoscopic and interventional device manufacturer that acquired Apollo Endosurgery. Comparable to Endogenex as an endoscopic procedure device manufacturer with established sales channels into gastroenterology and bariatric surgery — the same specialist channels Endogenex would target commercially.
- Olympus Corporation: Olympus is the global leader in endoscopy equipment and related therapeutic devices. Comparable to Endogenex as an endoscopic procedure ecosystem player and potential strategic partner or acquirer, with established relationships across the gastroenterology specialist channel Endogenex would target.
- Abbott Diabetes Care: Abbott Diabetes Care manufactures the FreeStyle Libre CGM, the leading CGM system globally. While not a direct mechanism competitor, Abbott represents a major incumbent in the non-pharmacologic T2D management market and a potential strategic acquirer of disruptive procedural therapies like Endogenex's pulsENDO system.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Endogenex social profiles
Digital presenceEndogenex compliance and trust
Trust signalCompliance2 records
Endogenex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Endogenex leadership team
Management profileNumber of profiles
Profiles9 records
Endogenex funding detail
Funding detailFunding overview
Funding rounds6 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Endogenex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Endogenex
What does Endogenex do?
Endogenex is developing the pulsENDO System, a catheter-based endoscopic medical device that delivers non-thermal pulsed electric fields to the mucosa and submucosa of the duodenum. The procedure targets poorly functioning signaling cells to induce regeneration of healthy cells, with the goal of restoring metabolic function and helping patients with type 2 diabetes regain control of their blood glucose levels. The system is investigational, not yet approved for commercial sale, and is being evaluated in the pivotal ReCET Clinical Study for FDA approval.
Is Endogenex a public or private company?
Endogenex is a private company. It is classified as venture growth investor backed and is currently operating.
When was Endogenex founded?
Endogenex was founded in 2002. It employs 11 to 50 people.
Where is Endogenex based?
Endogenex is headquartered in Plymouth, United States, in the North America region.
How does Endogenex make money?
One revenue line is on record: medical Device Sales (Future).
Who are Endogenex's main competitors?
Fractyl Health is listed as a direct peer. Emerging players are Allurion Technologies, Spatz Medical and ReShape Lifesciences. Broad incumbents are Medtronic, Dexcom, Insulet, Boston Scientific, Olympus Corporation and Abbott Diabetes Care.
Does Endogenex have an API?
No public API is recorded for Endogenex.
What industry is Endogenex in?
Endogenex's product category is Endoscopic Medical Devices for Metabolic Disease. Its primary akta.pro industry code is HLAHADAC, Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser), with a secondary code of HLAKADAA, Diabetes (General). Its NAICS code is 334510 and its SIC code is 3845.